Our Pricing

The Science Behind Mounjaro And Feeling Cold

Experiencing mounjaro and feeling cold UK is a common concern among patients starting tirzepatide treatment. At Cured Pharmacy, our UK clinical team regularly advises patients on this metabolic side effect, which stems from the medication's effect on energy expenditure and body composition changes during weight loss.

Why Does Mounjaro Make You Feel Cold?

Mounjaro (tirzepatide) influences your body's thermoregulation through multiple metabolic pathways. As a dual GIP/GLP-1 receptor agonist, tirzepatide reduces caloric intake whilst simultaneously altering how your body generates and conserves heat [1]. When you consume fewer calories, your basal metabolic rate naturally decreases as an adaptive response, reducing the amount of heat your body produces through metabolic processes.

Clinical observations from the SURPASS trials showed that patients experiencing significant weight loss on tirzepatide often reported increased cold sensitivity, particularly during the first 12-16 weeks of treatment [1]. This phenomenon occurs because subcutaneous fat, which serves as insulation, decreases substantially during treatment. In SURPASS-3, participants lost an average of 22.5% of their body weight over 72 weeks, representing considerable reduction in the body's natural thermal barrier [2].

Additionally, tirzepatide's effect on thyroid hormone metabolism may contribute to cold sensitivity. Whilst the medication does not directly suppress thyroid function, the caloric restriction and rapid weight loss can temporarily reduce peripheral conversion of T4 to T3, the active thyroid hormone responsible for maintaining metabolic rate and body temperature [3].

Metabolic Changes During Mounjaro Treatment

How Tirzepatide Affects Energy Expenditure

Tirzepatide's dual-action mechanism activates both GIP and GLP-1 receptors, creating a more pronounced metabolic shift than single-pathway medications like semaglutide. This enhanced effect leads to greater reductions in resting energy expenditure, which directly correlates with decreased heat production [1]. Your body essentially becomes more energy-efficient, burning fewer calories at rest and consequently generating less thermal energy.

Research indicates that for every kilogram of weight lost, basal metabolic rate decreases by approximately 20-30 kcal per day. With average weight losses of 15-20 kg in clinical trials, this represents a significant reduction in daily heat generation [2]. This metabolic adaptation is a normal physiological response and typically stabilises once weight loss plateaus.

Body Composition Changes and Cold Sensitivity

The relationship between mounjaro and feeling cold becomes particularly noticeable as subcutaneous fat diminishes. Fat tissue functions as highly effective insulation, and its loss exposes you to greater heat dissipation. Patients losing substantial amounts of visceral and subcutaneous fat often report feeling colder in environments they previously found comfortable [3].

DEXA scan studies of patients on GLP-1 receptor agonists demonstrate that approximately 70-75% of weight lost comprises adipose tissue, with the remainder being lean mass and water. This preferential fat loss, whilst metabolically beneficial, reduces your body's thermal buffer zone [2]. The effect is most pronounced in patients who achieve rapid initial weight loss during the dose-escalation phase.

Interestingly, brown adipose tissue (BAT), which generates heat through non-shivering thermogenesis, may also be affected during significant weight loss. Whilst tirzepatide does not directly suppress BAT activity, the overall reduction in adipose tissue mass can impact your body's capacity for adaptive thermogenesis [3].

Managing Cold Sensitivity on Mounjaro

Practical Strategies for UK Patients

Most patients find that cold sensitivity improves after 3-4 months as their body adapts to the new metabolic state. During the adjustment period, layering clothing, maintaining adequate hydration, and consuming warm beverages throughout the day can help manage discomfort. Our superintendent pharmacist Tarun Kumar regularly advises patients to monitor their thyroid function if cold intolerance becomes severe or persistent.

Ensuring adequate protein intake (1.2-1.6g per kilogram of body weight) helps preserve lean muscle mass, which generates more metabolic heat than fat tissue. Regular physical activity, particularly resistance training, also supports metabolic rate maintenance and can partially offset the decrease in resting energy expenditure [4].

When to Seek Medical Advice About Feeling Cold

Whilst mild cold sensitivity is expected during mounjaro and feeling cold UK treatment, certain symptoms warrant clinical review. If you experience extreme cold intolerance accompanied by fatigue, hair loss, dry skin, or unexplained weight gain despite continued medication use, these may indicate thyroid dysfunction requiring assessment [3].

Your UK prescriber should evaluate persistent cold sensitivity lasting beyond 16 weeks of stable dosing, particularly if accompanied by other concerning symptoms. At Cured Pharmacy, our clinical team can arrange thyroid function testing through your GP if clinically indicated. It is important to distinguish between normal adaptive cold sensitivity and potential underlying conditions.

Patients with pre-existing thyroid conditions require closer monitoring during tirzepatide treatment. If you have hypothyroidism managed with levothyroxine, your prescriber may need to adjust your thyroid medication dose as your weight decreases, as thyroid hormone requirements often change with significant weight loss [4].

Comparing Cold Sensitivity Across Weight Loss Treatments

Mounjaro vs Other Injectable Medications

Cold sensitivity is reported across all GLP-1 receptor agonist medications, including Wegovy (semaglutide) and Saxenda (liraglutide), though the incidence appears higher with tirzepatide due to its greater efficacy in weight reduction. The dual-action mechanism of Mounjaro produces more substantial metabolic changes, which correlates with more pronounced thermoregulatory effects [1][2].

Patients using oral weight loss medications like Orlistat or Mysimba typically report less cold sensitivity, as these medications work through different mechanisms that do not significantly impact metabolic rate or produce such rapid fat loss. However, they also demonstrate lower efficacy in clinical trials compared to injectable GLP-1 treatments.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Rosenstock, J., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6
3. Rosenbaum, M., & Leibel, R. L. (2010). Adaptive thermogenesis in humans. International Journal of Obesity, 34(Suppl 1), S47–S55. https://doi.org/10.1038/ijo.2010.184
4. Müller, M. J., et al. (2016). Metabolic adaptation to caloric restriction and subsequent refeeding: the Minnesota Starvation Experiment revisited. American Journal of Clinical Nutrition, 102(4), 807–819. https://doi.org/10.3945/ajcn.115.109173

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.